Physician profile
Ayodeji Adeleke Dina
NPI 1699453498
$26,017.12
in general payments reported to CMS, 2019-2025
7 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,902 · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $18K · Food and Beverage: $6,818 · Education: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $18,347.31 |
| Food and Beverage | $6,817.78 |
| Education | $852.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,177.26 | 2023-2025 | Ensite Precision, Ensite, Aveir |
| Medtronic, INC. | $9,070.91 | 2023-2025 | Micra, Selectsecure, Cobalt Dr Mri Surescan |
| Medical Device Business Services, INC. | $3,032.28 | 2023-2024 | Carto 3 |
| Philips North America LLC | $1,701.26 | 2025 | Igt Devices Undivided, Lm Undivided |
| Boston Scientific Corporation | $1,124.33 | 2023-2025 | Versacross Access Solution, S-Icd System Magnet |
| Biosense Webster, INC. | $837.76 | 2025 | Carto 3 |
| Cardiva Medical, INC. | $73.32 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayodeji Dina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.